Trilogy offers top-quality products and custom services. Our innovative in vitro assays complement cell-based methods, providing valuable insights in TPD workflows. We feature HTS-compatible reagents and assays for screening and mechanistic studies, including highly active enzymes such as E3 ligases DCAF16, KLHDC2, FBXO22, FBXO31, and FEM1B. Our approaches incorporate HTRF, second-generation Alpha, spectral shift readouts, and multi-component substrate ubiquitylation assays, ensuring comprehensive and reliable data for your research needs.
In vitro proximity assays are valuable in drug discovery workflows because they help identify and characterize the interactions between small molecules and their biological targets. These assays can detect whether a compound binds to or influences the proximity of two or more proteins, which is useful for understanding mechanisms of action and optimizing lead compounds. Orthogonal to cell-based assays, which frequently supply a “yes or no” readout with little mechanistic insight, in vitro assays allow precise control over experimental variables such as compound concentration, environment, and assay components. These assays are highly specific, sensitive, and rapid, making them ideal for high-throughput screening campaigns and mechanistic studies. A wide variety of HTS-amenable assay formats are available for in vitro assays, such as AlphaLISA (Amplified Luminescent Proximity Homogeneous Assay), HTRF (Homogeneous Time-Resolved Fluorescence), FRET (Förster Resonance Energy Transfer) and FP (Fluorescence Polarization), complementing other biophysical techniques such as SPR (Surface Plasmon Resonance), ITC (Isothermal Titration Calorimetry), TSA (Thermal Shift Assay) and Spectral Shift.
